Boston, MA · Founded 2022 · Privately Held (backing)
Developer of late-stage preclinical drugs designed for oral therapy for obesity, diabetes, and rare diseases. Syntis Bio is based in Boston, MA and was founded in 2022. It was valued at $67 million at its early-stage round in Jun 2025, the last priced event on record. It has raised $48.4 million across 3 recorded rounds; the latest was a $25 million early-stage round in Jun 2025.
PMV mark · valuation
$67.0M
Oct 2026
Priced at
its early-stage round
Jun 2025
Total raised
$48.4M
Last round
Early Stage VC
Jun 2025
Team — not yet on record
No current team members for Syntis Bio are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Syntis Bio with a free account
·The complete investor list: 12 names
·Watch Syntis Bio: the Monday email on marks, rounds and moves
